Osteoporosis drugs in real-world clinical practice: an analysis of persistence

被引：30

作者：

Iolascon, Giovanni ^{[1
]}

Gimigliano, Francesca ^{[1
]}

Orlando, Valentina ^{[2
]}

Capaldo, Annarita ^{[1
]}

Di Somma, Carolina ^{[3
]}

Menditto, Enrica ^{[2
]}

机构：

[1] Univ Naples 2, Dept Med & Surg Specialties & Dent, Naples, Italy

[2] Univ Naples Federico II, Dept Pharm, Ctr Pharmacoecon & Drug Utilizat CIRFF, Naples, Italy

[3] IRCCS, SDN Fdn, Naples, Italy

来源：

AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2013年 / 25卷

关键词：

Osteoporosis; Persistence; Database; Drug utilization; ADHERENCE; THERAPY; FRACTURE; DETERMINANTS; POPULATION; MANAGEMENT;

D O I：

10.1007/s40520-013-0127-5

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The aim of our retrospective cohort study is to analyze the persistence rates in relation to antiosteoporotic drugs using administrative databases in the Campania Region. Patients, aged >= 40 years, were included if at least one prescription for any antiosteoporotic drugs had been filled in between January 1, 2009 and December 31, 2009. Overall, 37,594 patients were incident users of antiosteoporotic drugs. Among them, 15,978 patients had undergone spot-therapies. A total of 2,618 (14.1 %) were classified as switchers. Switching rates were highest for patients taking Alendronate 18.9 or Strontium Ranelate 15.0 and lower for patients taking Ibandronate 12.8 or Risedronate 10.8. In the overall population, 33.5 % of subjects were still on therapy after 6 months. At 1 year, persistence rates were: Ibandronate 21.6 %, Risedronate 15.8 %, Alendronate + Vitamin D 15.7 %, Raloxifene 14.3 %, Alendronate 12.6 % and Strontium Ranelate 5.0 %.

引用

页码：S137 / S141

页数：5

共 15 条

[11] Determinants of adherence to osteoporosis treatment in clinical practice [J].

Rossini, M. ;

Bianchi, G. ;

Di Munno, O. ;

Giannini, S. ;

Minisola, S. ;

Sinigaglia, L. ;

Adami, S. .

OSTEOPOROSIS INTERNATIONAL, 2006, 17 (06) :914-921

[12] Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe [J].

Siris, Ethel S. ;

Selby, Peter L. ;

Saag, Kenneth G. ;

Borgstrom, Fredrik ;

Herings, Ron M. C. ;

Silverman, Stuart L. .

AMERICAN JOURNAL OF MEDICINE, 2009, 122 (02) :3-13

[13] Adherence to anti-osteoporotic therapies: role and determinants of "spot therapy" [J].

Tafaro, L. ;

Nati, G. ;

Leoni, E. ;

Baldini, R. ;

Cattaruzza, M. S. ;

Mei, M. ;

Falaschi, P. .

OSTEOPOROSIS INTERNATIONAL, 2013, 24 (08) :2319-2323

[14] Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan [J].

Wade, Sally W. ;

Curtis, Jeffrey R. ;

Yu, Jingbo ;

White, Jeffrey ;

Stolshek, Bradley S. ;

Merinar, Claire ;

Balasubramanian, Akhila ;

Kallich, Joel D. ;

Adams, John L. ;

Viswanathan, Hema N. .

BONE, 2012, 50 (04) :870-875

[15] Compliance with pharmacologic therapy for osteoporosis [J].

Yood, RA ;

Emani, S ;

Reed, JI ;

Lewis, BE ;

Charpentier, M ;

Lydick, E .

OSTEOPOROSIS INTERNATIONAL, 2003, 14 (12) :965-968

← 1 2 →